ID

35168

Beskrivning

Study ID: 107022 Clinical Study ID: 107022 Study Title: A phase IIb, controlled, randomised, multicenter, single blind study to demonstrate the Non-Inferiority of the low dose influenza vaccine with or without adjuvant AS03 compared with Fluarix (GlaxoSmithKline Biologicals) administered intramuscularly in elderly >= 60 years Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00321373 Study Link: https://clinicaltrials.gov/ct2/show/NCT00321373 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Candidate Influenza Vaccine GSK1247446A - 2 different formulations Trade Name: FluarixTM Study Indication: Influenza The purpose of his form is to document if a blood sample for HI antibody determination has been taken. Visit 1: Day 0, Pre vaccination Visit 2: Day 21, Post vaccination 1 Phone contact: Day 30, post vaccination 1 Visit 3: Day 180, post vaccination 1 Visit 1 and 2 are part of the study: "Demonstration of the Non-Inferiority of the Low Dose Influenza Vaccine Compared with Fluarix NCT00321373" This study is a LONG-TERM FOLLOW-UP to the PREVIOUS STUDY 107022 (FLU-LD-001).

Länk

https://clinicaltrials.gov/ct2/show/NCT00321373

Nyckelord

Versioner (3)

1. 2019-02-13 2019-02-13 -
2. 2019-02-20 2019-02-20 - Sarah Riepenhausen
3. 2019-02-25 2019-02-25 - Sarah Riepenhausen

Rättsinnehavare

GlaxoSmithKline

Uppladdad den

20 februari 2019

DOI

För en begäran logga in.

Licens